JP7585193B2 - 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 - Google Patents

血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 Download PDF

Info

Publication number
JP7585193B2
JP7585193B2 JP2021510984A JP2021510984A JP7585193B2 JP 7585193 B2 JP7585193 B2 JP 7585193B2 JP 2021510984 A JP2021510984 A JP 2021510984A JP 2021510984 A JP2021510984 A JP 2021510984A JP 7585193 B2 JP7585193 B2 JP 7585193B2
Authority
JP
Japan
Prior art keywords
antibody
hae
weeks
treatment
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021510984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535161A (ja
JPWO2020047352A5 (enExample
Inventor
ルー，ペン
ナース，クリスティーナ
ハオ，シンミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2021535161A publication Critical patent/JP2021535161A/ja
Publication of JPWO2020047352A5 publication Critical patent/JPWO2020047352A5/ja
Priority to JP2024094996A priority Critical patent/JP2024113183A/ja
Application granted granted Critical
Publication of JP7585193B2 publication Critical patent/JP7585193B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021510984A 2018-08-30 2019-08-30 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 Active JP7585193B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024094996A JP2024113183A (ja) 2018-08-30 2024-06-12 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862725216P 2018-08-30 2018-08-30
US62/725,216 2018-08-30
US201962808612P 2019-02-21 2019-02-21
US62/808,612 2019-02-21
PCT/US2019/048961 WO2020047352A1 (en) 2018-08-30 2019-08-30 Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024094996A Division JP2024113183A (ja) 2018-08-30 2024-06-12 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用

Publications (3)

Publication Number Publication Date
JP2021535161A JP2021535161A (ja) 2021-12-16
JPWO2020047352A5 JPWO2020047352A5 (enExample) 2022-09-05
JP7585193B2 true JP7585193B2 (ja) 2024-11-18

Family

ID=67953889

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021510984A Active JP7585193B2 (ja) 2018-08-30 2019-08-30 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用
JP2024094996A Pending JP2024113183A (ja) 2018-08-30 2024-06-12 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024094996A Pending JP2024113183A (ja) 2018-08-30 2024-06-12 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用

Country Status (12)

Country Link
US (2) US20200109214A1 (enExample)
EP (1) EP3843840A1 (enExample)
JP (2) JP7585193B2 (enExample)
KR (1) KR20210053928A (enExample)
CN (1) CN113056304A (enExample)
AU (2) AU2019328324B2 (enExample)
BR (1) BR112021003789A2 (enExample)
CA (1) CA3110689A1 (enExample)
IL (1) IL281063A (enExample)
MA (1) MA53490A (enExample)
MX (1) MX2021002349A (enExample)
WO (1) WO2020047352A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024113183A (ja) * 2018-08-30 2024-08-21 武田薬品工業株式会社 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3459564T1 (sl) 2010-01-06 2022-06-30 Takeda Pharmaceutical Company Limited Proteini, ki vežejo plazemski kalikrein
JP2014506257A (ja) 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
CN111704672B (zh) 2013-03-15 2024-06-04 武田药品工业株式会社 抗血浆激肽释放酶抗体
EA038532B1 (ru) 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
IL295414B1 (en) 2014-03-27 2025-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN115297927A (zh) * 2020-01-13 2022-11-04 武田药品工业株式会社 血浆激肽释放酶抑制剂及其用于治疗儿科遗传性血管性水肿发作的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100679A1 (en) 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ES2227545T3 (es) 1994-01-11 2005-04-01 Dyax Corporation Proteinas y sus analogos del "dominio de kunitz" inhibidores de calicreina.
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE60333758D1 (de) 2002-06-07 2010-09-23 Dyax Corp Prevention und Verringerung von Ischemia
JP2014506257A (ja) * 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
CN111704672B (zh) * 2013-03-15 2024-06-04 武田药品工业株式会社 抗血浆激肽释放酶抗体
IL295414B1 (en) * 2014-03-27 2025-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
EP3286226A4 (en) * 2015-03-30 2018-12-05 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
EP3390825B1 (en) * 2015-12-18 2020-09-02 Graco Minnesota Inc. Bellows installation and retention method
MX2021002349A (es) * 2018-08-30 2021-05-31 Takeda Pharmaceuticals Co Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100679A1 (en) 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEENA BANERJI; ET AL，EFFECT OF LANADELUMAB COMPARED WITH PLACEBO ON PREVENTION OF HEREDITARY ANGIOEDEMA ATTACKS A RANDOMIZED CLINICAL TRIAL，JAMA，2018年11月27日，VOL:320,NR:20，PAGE(S):2108-2121，https://doi.org/10.1001/jama.2018.16773
MARIA BOVA; ET AL，LANADELUMAB INJECTION TREATMENT FOR THE PREVENTION OF HEREDITARY ANGIOEDEMA (HAE): DESIGN, DEVELOPMENT AND PLACE IN THERAPY，DRUG DESIGN, DEVELOPMENT AND THERAPY，2019年10月，VOL:13，PAGE(S):3635-3646，http://dx.doi.org/10.2147/DDDT.S192475
PAULA J. BUSSE; ET AL，EFFICACY AND SAFETY OF LANADELUMAB FOR PROPHYLACTIC TREATMENT IN ADOLESCENTS WITH HEREDITARY ANGIOEDEMA (HAE)，JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY，NL，2019年02月，VOL:143,NR:2，PAGE(S):AB43，https://doi.org/10.1016/j.jaci.2018.12.131

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024113183A (ja) * 2018-08-30 2024-08-21 武田薬品工業株式会社 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用

Also Published As

Publication number Publication date
EP3843840A1 (en) 2021-07-07
AU2019328324B2 (en) 2025-06-19
CA3110689A1 (en) 2020-03-05
US20230104754A1 (en) 2023-04-06
JP2021535161A (ja) 2021-12-16
IL281063A (en) 2021-04-29
US20200109214A1 (en) 2020-04-09
WO2020047352A1 (en) 2020-03-05
KR20210053928A (ko) 2021-05-12
MX2021002349A (es) 2021-05-31
JP2024113183A (ja) 2024-08-21
WO2020047352A8 (en) 2020-04-16
AU2025230807A1 (en) 2025-10-02
BR112021003789A2 (pt) 2021-05-18
CN113056304A (zh) 2021-06-29
AU2019328324A1 (en) 2021-04-29
MA53490A (fr) 2022-05-04

Similar Documents

Publication Publication Date Title
JP7585193B2 (ja) 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用
JP7426369B2 (ja) 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途
JP7309836B2 (ja) 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用
WO2020186132A1 (en) Treating hereditary angioedema attack with reduced dosage of antibodies binding to human plasma kallikrein
US20230192889A1 (en) Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
JP2025186458A (ja) 小児遺伝性血管性浮腫発作を治療するための血漿カリクレイン阻害剤及びその使用
EA048026B1 (ru) Ингибиторы калликреина плазмы и их применения для лечения приступа наследственного ангионевротического отека
EA045920B1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210427

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240613

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240702

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241106

R150 Certificate of patent or registration of utility model

Ref document number: 7585193

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150